MUC16 and ovarian carcinoma: However, Lee et al. and Morgan et al. recently reported using data from the CALYPSO Phase III trial and the ICON-8 Phase III trial that this CA-125 response criterion is a poor predictor of the effectiveness of chemotherapy in primary and recurrent ovarian cancer [12,13].